The New York Times report on bepirovirsen highlights a 20% functional cure rate in chronic hepatitis B patients, yet overlooks the underlying trial's limitations as a phase 2 randomized controlled study with roughly 457 participants across multiple arms, where HBsAg loss was sustained in only a subset without clear durability beyond 24 weeks post-treatment. This RCT design provides stronger causal evidence than prior observational cohorts but carries industry sponsorship risks from GSK, potentially influencing endpoint selection toward HBsAg clearance over harder outcomes like hepatocellular carcinoma incidence. Connecting to broader patterns, this aligns with earlier antisense oligonucleotide work in Yuen et al. (N Engl J Med 2022; sample size 457, multicenter RCT) while diverging from lower response rates in real-world Asian cohorts tracked in observational registries of 1,200 patients, where genotype C dominance reduced efficacy. A second key source, the 2023 EASL position paper on HBV functional cure endpoints, underscores that 1-in-5 responses may not scale to the 250 million global cases without addressing access in low-resource settings, a gap the NYT coverage misses entirely. Deeper analysis reveals missed opportunities around combination strategies with capsid inhibitors, as single-agent data show rebound in 80% of non-responders, and conflicts of interest in trial leadership could bias safety reporting on thrombocytopenia events observed at higher doses.